intensive insulin therapy to maintain normoglycemia

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Critical Illness

Conditions

Critical Illness

Trial Timeline

Mar 1, 2002 → Jun 1, 2005

NCT ID

NCT00115479

About intensive insulin therapy to maintain normoglycemia

intensive insulin therapy to maintain normoglycemia is a phase 2 stage product being developed by Novo Nordisk for Critical Illness. The current trial status is completed. This product is registered under clinical trial identifier NCT00115479. Target conditions include Critical Illness.

What happened to similar drugs?

4 of 9 similar drugs in Critical Illness were approved

Approved (4) Terminated (2) Active (3)

✅DaptomycinMerckApproved

✅Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.AmgenApproved

✅Colchicine (Colcrys®) + placebo + allopurinolRegeneron PharmaceuticalsApproved

✅Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35EBaxterApproved

🔄Apixaban + ASA + Clopidogrel 75mgPfizerPhase 3

🔄Rilonacept 80 mg + Rilonacept 160 mgRegeneron PharmaceuticalsPhase 3

❌Remodulin® (treprostinil sodium) InjectionUnited TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00115479	Phase 2	Completed	Mar 1, 2002	Jun 1, 2005	Critical Illness

Competing Products

13 competing products in Critical Illness

See all competitors

Product	Company	Stage	Hype Score
Daptomycin	Merck	Approved	43
Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose	Merck	Phase 1	29
Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.	Amgen	Approved	39
Midazolam + Dexmedetomidine	Pfizer	Pre-clinical	26
Apixaban + ASA + Clopidogrel 75mg	Pfizer	Phase 3	36
Colchicine (Colcrys®) + placebo + allopurinol	Regeneron Pharmaceuticals	Approved	43
Rilonacept 80 mg + Rilonacept 160 mg	Regeneron Pharmaceuticals	Phase 3	40
treprostinil dienthanolmine sustained release + Placebo	United Therapeutics	Phase 2	32
Remodulin® (treprostinil sodium) Injection	United Therapeutics	Phase 3	29
Olimel (5.7%E / N9E)	Baxter	Phase 3	29
Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E	Baxter	Approved	44
RJX + Placebo	ICON plc.	Phase 1	26
Ixmyelocel-T	Vericel	Phase 3	34